CoChat

Clinical Practice Pathways for Evaluation and Medication Choice for Attention-Deficit/Hyperactivity Disorder Symptoms in Autism Spectrum Disorders

Mahajan, Rajneesh, Bernal, Maria Pilar, Panzer, Rebecca, Whitaker, Agnes, Roberts, Wendy, Handen, Benjamin, Hardan, Antonio, Anagnostou, Evdokia, Veenstra-VanderWeele, Jeremy · 2012 · Pediatrics
Cited by 121

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND OBJECTIVE: Hyperactivity, impulsivity, and inattention (referred to as “ADHD [attention-deficit/hyperactivity disorder] symptoms”) occur in 41% to 78% of children with autism spectrum disorders (ASDs). These symptoms often affect quality of life, interfering with learning or interventions that target primary ASD symptoms. This practice pathway describes the guidelines for evaluation and treatment of children and adolescents with ASD and comorbid ADHD symptoms. METHODS: Current research in this area is limited, and, therefore, these recommendations are based on a systematic literature review and expert consensus in the Autism Speaks Autism Treatment Network Psychopharmacology Committee. RESULTS: The recommended practice pathway includes the Symptom Evaluation Pathway for systematic assessment of ADHD symptoms across settings; examination for comorbid sleep, medical, or psychiatric comorbidities that may contribute to symptoms; and evaluation of behavioral interventions that may ameliorate these symptoms. For children for whom medication is being considered to target the ADHD symptoms, the medication choice pathway provides guidance on the selection of the appropriate agent based on a review of available research, assessment of specific advantages and disadvantages of each agent, and dosing considerations. CONCLUSIONS: These recommendations provide a framework for primary care providers treating children who have ASD and ADHD symptoms. Our systematic review of the current evidence indicates the need for more randomized controlled trials of the medications for ADHD symptoms in ASD. There will also be a need for studies of the effectiveness of these practice pathways in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1542/peds.2012-0900j

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 34

  1. Jeste, 2011, The neurology of autism spectrum disorders., Curr Opin Neurol, 24, 132, 10.1097/WCO.0b013e3283446450 · DOI · Paper page
  2. Gillberg, 2000, Autism and Asperger syndrome: coexistence with other clinical disorders., Acta Psychiatr Scand, 102, 321, 10.1034/j.1600-0447.2000.102005321.x · DOI · Paper page
  3. First, 2005, Mutually exclusive versus co-occurring diagnostic categories: the challenge of diagnostic comorbidity., Psychopathology, 38, 206, 10.1159/000086093 · DOI · Paper page
  4. Matson, 2007, Comorbid psychopathology with autism spectrum disorder in children: an overview., Res Dev Disabil, 28, 341, 10.1016/j.ridd.2005.12.004 · DOI · Paper page
  5. Gjevik, 2011, Kiddie-SADS reveals high rates of DSM-IV disorders in children and adolescents with autism spectrum disorders., J Autism Dev Disord, 41, 761, 10.1007/s10803-010-1095-7 · DOI · Paper page
  6. Yoshida, 2004, The clinical necessity for assessing attention deficit/hyperactivity disorder (AD/HD) symptoms in children with high-functioning pervasive developmental disorder (PDD)., Eur Child Adolesc Psychiatry, 13, 307, 10.1007/s00787-004-0391-1 · DOI · Paper page
  7. American Psychiatric Association, 2000, Diagnostic and Statistical Manual of Medical Disorders
  8. American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement., 2001, Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder., Pediatrics, 108, 1033, 10.1542/peds.108.4.1033 · DOI · Paper page
  9. Ghuman, 2009, Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders., J Child Adolesc Psychopharmacol, 19, 329, 10.1089/cap.2008.0137 · DOI · Paper page
  10. Filipek, 2000, Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society., Neurology, 55, 468, 10.1212/WNL.55.4.468 · DOI · Paper page
  11. Wolraich, 1998, Obtaining systematic teacher reports of disruptive behavior disorders utilizing DSM-IV., J Abnorm Child Psychol, 26, 141, 10.1023/A:1022673906401 · DOI · Paper page
  12. Wolraich, 2003, Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a referred population., J Pediatr Psychol, 28, 559, 10.1093/jpepsy/jsg046 · DOI · Paper page
  13. Geller, 2007, Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder., J Am Acad Child Adolesc Psychiatry, 46, 1119, 10.1097/chi.0b013e3180ca8385 · DOI · Paper page
  14. Aman, 2003, Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio., J Autism Dev Disord, 33, 527, 10.1023/A:1025883612879 · DOI · Paper page
  15. Siegel, 2011, Psychotropic medications in children with autism spectrum disorders: a systematic review and synthesis for evidence-based practice., J Autism Dev Disord
  16. Handen, 2000, Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder., J Autism Dev Disord, 30, 245, 10.1023/A:1005548619694 · DOI · Paper page
  17. Troost, 2005, Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study., J Am Acad Child Adolesc Psychiatry, 44, 1137, 10.1097/01.chi.0000177055.11229.76 · DOI · Paper page
  18. Shea, 2004, Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders., Pediatrics, 114, e634, 10.1542/peds.2003-0264-F · DOI · Paper page
  19. Marcus, 2009, A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder., J Am Acad Child Adolesc Psychiatry, 48, 1110, 10.1097/CHI.0b013e3181b76658 · DOI · Paper page
  20. Akhondzadeh, 2010, Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism., Prog Neuropsychopharmacol Biol Psychiatry, 34, 32, 10.1016/j.pnpbp.2009.09.012 · DOI
  21. Rezaei, 2010, Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder., Prog Neuropsychopharmacol Biol Psychiatry, 34, 1269, 10.1016/j.pnpbp.2010.07.005 · DOI
  22. Niederhofer, 2003, Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder., Hum Psychopharmacol, 18, 389, 10.1002/hup.491 · DOI · Paper page
  23. Zeiner, 2011, Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder., Acta Paediatr, 100, 1258, 10.1111/j.1651-2227.2011.02263.x · DOI · Paper page
  24. Scahill, 2006, A prospective open trial of guanfacine in children with pervasive developmental disorders., J Child Adolesc Psychopharmacol, 16, 589, 10.1089/cap.2006.16.589 · DOI · Paper page
  25. Malone, 2002, Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness., J Am Acad Child Adolesc Psychiatry, 41, 140, 10.1097/00004583-200202000-00007 · DOI
  26. Masi, 2001, Open trial of risperidone in 24 young children with pervasive developmental disorders., J Am Acad Child Adolesc Psychiatry, 40, 1206, 10.1097/00004583-200110000-00015 · DOI
  27. Research Units on Pediatric Psychopharmacology Autism Network, 2005, Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months., Am J Psychiatry, 162, 1361, 10.1176/appi.ajp.162.7.1361 · DOI · Paper page
  28. Gagliano, 2004, Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications., J Child Adolesc Psychopharmacol, 14, 39, 10.1089/104454604773840472 · DOI
  29. Kim, 2010, Retrospective case series of aripiprazole augmentation in pervasive developmental disorders., Psychiatry Investig, 7, 220, 10.4306/pi.2010.7.3.220 · doi:10.4306/pi.2010.7.3.220
  30. Kemner, 2002, Open-label study of olanzapine in children with pervasive developmental disorder., J Clin Psychopharmacol, 22, 455, 10.1097/00004714-200210000-00003 · DOI
  31. Malone, 2007, Ziprasidone in adolescents with autism: an open-label pilot study., J Child Adolesc Psychopharmacol, 17, 779, 10.1089/cap.2006.0126 · DOI · Paper page
  32. Fido, 2008, Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait., Med Princ Pract, 17, 415, 10.1159/000141508 · DOI
  33. Erickson, 2007, A retrospective study of memantine in children and adolescents with pervasive developmental disorders., Psychopharmacology (Berl), 191, 141, 10.1007/s00213-006-0518-9 · DOI · Paper page
  34. Rugino, 2002, Levetiracetam in autistic children: an open-label study., J Dev Behav Pediatr, 23, 225, 10.1097/00004703-200208000-00006 · DOI

Cited by

See all 121

Metadata

Authors
Mahajan, R., Bernal, M. P., Panzer, R., Whitaker, A., Roberts, W., Handen, B., Hardan, A., Anagnostou, E., & Veenstra-VanderWeele, J.
Venue
Pediatrics
Published
2012-11-01
Volume
130
Issue
Supplement_2
Pages
S125-S138
ISSN
  • 0031-4005 (ISSN-L)
  • 1098-4275
OpenAlex
W2170334130
Cited by
121
References
30
FWCI
6.15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Practice Pathways for Evaluation and Medication Choice for Attention-Deficit/Hyperactivity Disorder Symptoms in Autism Spectrum Disorders. https://app.cochat.ai/papers/10.1542/peds.2012-0900j
The paper
Mahajan, R., Bernal, M. P., Panzer, R., Whitaker, A., Roberts, W., Handen, B., Hardan, A., Anagnostou, E., & Veenstra-VanderWeele, J. (2012). Clinical Practice Pathways for Evaluation and Medication Choice for Attention-Deficit/Hyperactivity Disorder Symptoms in Autism Spectrum Disorders. Pediatrics. https://doi.org/10.1542/peds.2012-0900j

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.